Multi-omics Analysis: Paving the Path Toward Achieving Precision Medicine in Cancer Treatment and Immuno-oncology

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2022 Oct 28

PMID 36304921

Authors

Virgile Raufaste-Cazavieille

Raoul Santiago

Arnaud Droit

Affiliations

Soon will be listed here.

Abstract

The acceleration of large-scale sequencing and the progress in high-throughput computational analyses, defined as omics, was a hallmark for the comprehension of the biological processes in human health and diseases. In cancerology, the omics approach, initiated by genomics and transcriptomics studies, has revealed an incredible complexity with unsuspected molecular diversity within a same tumor type as well as spatial and temporal heterogeneity of tumors. The integration of multiple biological layers of omics studies brought oncology to a new paradigm, from tumor site classification to pan-cancer molecular classification, offering new therapeutic opportunities for precision medicine. In this review, we will provide a comprehensive overview of the latest innovations for multi-omics integration in oncology and summarize the largest multi-omics dataset available for adult and pediatric cancers. We will present multi-omics techniques for characterizing cancer biology and show how multi-omics data can be combined with clinical data for the identification of prognostic and treatment-specific biomarkers, opening the way to personalized therapy. To conclude, we will detail the newest strategies for dissecting the tumor immune environment and host-tumor interaction. We will explore the advances in immunomics and microbiomics for biomarker identification to guide therapeutic decision in immuno-oncology.

Citing Articles

Multi-omics approaches for understanding gene-environment interactions in noncommunicable diseases: techniques, translation, and equity issues.

Alemu R, Sharew N, Arsano Y, Ahmed M, Tekola-Ayele F, Mersha T Hum Genomics. 2025; 19(1):8.

PMID: 39891174 PMC: 11786457. DOI: 10.1186/s40246-025-00718-9.

Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy.

Chadokiya J, Chang K, Sharma S, Hu J, Lill J, Dionne J Front Immunol. 2025; 15():1520860.

PMID: 39850874 PMC: 11753970. DOI: 10.3389/fimmu.2024.1520860.

Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification.

Hachem S, Yehya A, El Masri J, Mavingire N, Johnson J, Dwead A Biology (Basel). 2024; 13(10).

PMID: 39452071 PMC: 11504278. DOI: 10.3390/biology13100762.

Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia.

Mavridou D, Psatha K, Aivaliotis M J Pers Med. 2024; 14(8).

PMID: 39202022 PMC: 11355716. DOI: 10.3390/jpm14080831.

Applications of Multimodal Artificial Intelligence in Non-Hodgkin Lymphoma B Cells.

Isavand P, Aghamiri S, Amin R Biomedicines. 2024; 12(8).

PMID: 39200217 PMC: 11351272. DOI: 10.3390/biomedicines12081753.

References

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

Zhao Y, Gao Y, Xu X, Zhou J, Wang H . Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma. BMC Cancer. 2021; 21(1):257. PMC: 7942004. DOI: 10.1186/s12885-021-07888-4. View

Pucher B, Zeleznik O, Thallinger G . Comparison and evaluation of integrative methods for the analysis of multilevel omics data: a study based on simulated and experimental cancer data. Brief Bioinform. 2018; 20(2):671-681. DOI: 10.1093/bib/bby027. View

Chu J, Sun N, Hu W, Chen X, Yi N, Shen Y . The Application of Bayesian Methods in Cancer Prognosis and Prediction. Cancer Genomics Proteomics. 2021; 19(1):1-11. PMC: 8717957. DOI: 10.21873/cgp.20298. View

Derosa L, Routy B, Thomas A, Iebba V, Zalcman G, Friard S . Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022; 28(2):315-324. PMC: 9330544. DOI: 10.1038/s41591-021-01655-5. View

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M . Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med. 2019; 25(10):1519-1525. DOI: 10.1038/s41591-019-0583-3. View

Hoadley K, Yau C, Wolf D, Cherniack A, Tamborero D, Ng S . Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014; 158(4):929-944. PMC: 4152462. DOI: 10.1016/j.cell.2014.06.049. View

Menyhart O, Gyorffy B . Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021; 19:949-960. PMC: 7868685. DOI: 10.1016/j.csbj.2021.01.009. View

Baruch E, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L . Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2020; 371(6529):602-609. DOI: 10.1126/science.abb5920. View

10.

Canzler S, Schor J, Busch W, Schubert K, Rolle-Kampczyk U, Seitz H . Prospects and challenges of multi-omics data integration in toxicology. Arch Toxicol. 2020; 94(2):371-388. DOI: 10.1007/s00204-020-02656-y. View

11.

Mo Q, Li R, Adeegbe D, Peng G, Chan K . Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol. 2020; 3(1):784. PMC: 7746703. DOI: 10.1038/s42003-020-01491-2. View

12.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

13.

Franzosa E, Morgan X, Segata N, Waldron L, Reyes J, Earl A . Relating the metatranscriptome and metagenome of the human gut. Proc Natl Acad Sci U S A. 2014; 111(22):E2329-38. PMC: 4050606. DOI: 10.1073/pnas.1319284111. View

14.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

15.

Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K . B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019; 10(1):4186. PMC: 6744450. DOI: 10.1038/s41467-019-12160-2. View

16.

Janda J, Abbott S . 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. J Clin Microbiol. 2007; 45(9):2761-4. PMC: 2045242. DOI: 10.1128/JCM.01228-07. View

17.

Anderson P, Gadgil R, Johnson W, Schwab E, Davidson J . Reducing variability of breast cancer subtype predictors by grounding deep learning models in prior knowledge. Comput Biol Med. 2021; 138:104850. DOI: 10.1016/j.compbiomed.2021.104850. View

18.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

19.

Chauvel C, Novoloaca A, Veyre P, Reynier F, Becker J . Evaluation of integrative clustering methods for the analysis of multi-omics data. Brief Bioinform. 2019; 21(2):541-552. DOI: 10.1093/bib/bbz015. View

20.

Herrmann M, Probst P, Hornung R, Jurinovic V, Boulesteix A . Large-scale benchmark study of survival prediction methods using multi-omics data. Brief Bioinform. 2020; 22(3). PMC: 8138887. DOI: 10.1093/bib/bbaa167. View